Digestive health remains the market-leading benefit targeted by probiotics and the number one reason for consumers to buy nutraceuticals. Over the past 20 years, an increasing amount of evidence on probiotics efficacy has reinforced probiotics awareness and lead to millions of people taking probiotics for their digestive health.
Last January, a new published independent clinical study confirmed the efficacy of our “gut-friendly” probiotic yeast Saccharomyces cerevisiae CNCM I-3856 (marketed as ibSium®) to support digestive health.
Indeed, this study confirms the beneficial effects of this proprietary strain for abdominal pain management and bowel habits improvements in the general IBS population.
With this clinical study, ibSium® confirms its positioning as one of the most documented probiotics to support intestinal comfort.
If you wish to receive a copy to introduce ibSium® benefits to your customers, please fill in the contact form and ask for it!
